Advances in Antitumor Molecular-Targeted Agents of Urological Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 4067
Special Issue Editors
Interests: urological and gynecological cancers
Special Issue Information
Dear Colleagues,
According to tumor malignancy statistics, the occurrence of urological cancers is continuously increasing in Western countries; this is mainly due to the increased life expectancy in these geographic areas, but other factors also contribute to this growth.
An understanding of dysregulated pathways and the identification of potential biomarkers for the treatment of urological cancers have facilitated the identification of new targets and pathways for novel-targeted therapies, including immunomodulatory agents and agents that target angiogenesis, growth factor receptors, and epigenetic pathways. The aim of this Special Issue is to present recent advances in antitumor molecular-targeted agents in prostate, kidney, bladder, and testicular cancer, and to present clinical evidence of their use, whether alone or in combination.
Dr. Maria Giuseppa Vitale
Dr. Roberto Sabbatini
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- targeted therapy
- urological cancers
- angiogenesis
- prostate, kidney, bladder, and testicular cancer
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
